breast cancer
Washington, DC -- With the goal of tailoring cancer interventions for the individual, researchers at the Lombardi Comprehensive Cancer Center at Georgetown have published the results of a prospective study that validates the use of a simple blood test to help doctors more reliably assess treatment effectiveness for patients with metastatic breast cancer.
PHILADELPHIA -- In a one-two punch, a familiar diabetes drug reduced tumors faster and prolonged remission in mice longer than chemotherapy alone by targeting cancer stem cells, Harvard Medical School researchers reported in the September 14 online first edition of Cancer Research, a journal of the American Association for Cancer Research.
BOSTON, Mass. (September 14, 2009) -- In a one-two punch, a familiar diabetes drug reduced tumors faster and prolonged remission in mice longer than chemotherapy alone, apparently by targeting cancer stem cells, report Harvard Medical School researchers in the Sept. 14 advance online Cancer Research.
A new study finds that there is little information available about the use of new testing technologies and targeted therapies in breast cancer, specifically the anti-cancer drug trastuzumab (Herceptin).
A team of scientists led by researcher Brenda Hernandez, Ph.D., M.P.H. -- an assistant professor at the University of Hawai'i at Mānoa's Cancer Research Center of Hawai'i -- has reported that body mass in younger and older adulthood, and weight gain between these life periods, may influence a man's risk for prostate cancer.
ANN ARBOR, Mich.---The growth of cancerous tumors is fueled, at least in part, by the buildup of free radicals---highly reactive oxygen-containing molecules.
HOUSTON - While Fanconi anemia (FA) is a rare and dangerous disease, new laboratory research at The University of Texas M. D. Anderson Cancer Center shows it may lead researchers toward clues in more common diseases, including highly hereditary types of breast cancer.
SEATTLE -- It is well known that survivors of breast cancer have a much higher risk of developing a second breast cancer than women in the general population have of developing a first breast cancer.
HOUSTON ― Active, but non-invasive breast cancer is set free to roam as invasive breast cancer when an overexpressed protein converts it to a different cell type, scientists at The University of Texas M. D. Anderson Cancer Center report in the Sept. 9 issue of the journal Cancer Cell.
A new study identifies a molecule that acts cooperatively with a well known oncoprotein to drive progression of noninvasive breast cancer to metastatic, life-threatening disease.
PHILADELPHIA -- Use of the molecularly targeted agent lapatinib to delay tumor growth and improve the survival of patients with inoperable hepatocellular carcinoma, or liver cancer, only benefited certain subgroups of patients.
A molecular signature that helps account for the aggressive behavior of a variety of cancers such as pancreatic, breast and melanoma may also predict the likelihood of successful treatment with a particular anti-cancer drug.
DURHAM, N.C. -- One person's breast cancer is not the same as another person's, because the gene mutations differ in each tumor. That makes it difficult to match the best therapy with the individual patient.
Vaccinating women against the human papillomavirus (HPV) may prevent some forms of breast cancer and save tens of thousands of lives each year, new Australian research suggests.
WEST LAFAYETTE, Ind. - Dietary supplements claiming to help postmenopausal women with bone health may not be doing what they say, according to new research from Purdue University.
